Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity.

Br J Cancer · 2013 · PMC3629418 · PMID 23492685

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Effect of number of treatments of PRRT on survival An additional analysis into the effect of the number of 90 Yttrium PRRT treatments administered showed a trend of increasing OS with each additional 90 Yttrium treatment (16 vs 20 vs 51 months for treatment 1, 2 and 3, respectively), however, this was not statistically significant ( P =0.081).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.